Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has been given an average rating of “Moderate Buy” by the four research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and three have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $3.3333.

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Friday, March 27th. Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of Cognition Therapeutics in a report on Friday, March 27th. Finally, raised Cognition Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently bought and sold shares of CGTX. Raymond James Financial Inc. increased its stake in Cognition Therapeutics by 34.7% during the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after purchasing an additional 7,641 shares in the last quarter. Bryn Mawr Trust Advisors LLC lifted its stake in shares of Cognition Therapeutics by 69.1% in the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after buying an additional 16,129 shares in the last quarter. Jones Financial Companies Lllp bought a new position in shares of Cognition Therapeutics in the third quarter valued at $25,000. Essex Financial Services Inc. grew its holdings in shares of Cognition Therapeutics by 100.0% during the first quarter. Essex Financial Services Inc. now owns 40,000 shares of the company’s stock valued at $30,000 after buying an additional 20,000 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new position in shares of Cognition Therapeutics during the third quarter valued at about $27,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Trading Down 5.0%

NASDAQ:CGTX opened at $1.14 on Friday. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The stock has a market capitalization of $102.03 million, a price-to-earnings ratio of -4.75 and a beta of 1.81. The firm has a fifty day simple moving average of $1.07 and a two-hundred day simple moving average of $1.29.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. Equities analysts predict that Cognition Therapeutics will post -0.28 earnings per share for the current fiscal year.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.